Falcon Peps / Research journal
Myostatin and activin-pathway research, body composition and functional outcomes. Muscle mass is not the same as strength or performance.
2 articles · Primary sources linked
The motor-function results, current US approval and safety context—and why SMA findings cannot be converted into healthy-adult performance claims.
Read the research : Apitegromab after SAPPHIRE: what the SMA evidence meansWhat activin-receptor studies show about body composition, and why adding lean mass does not automatically improve strength or mobility.
Read the research : Bimagrumab: fat loss, lean mass and the function questionFalcon Peps publishes source-linked research summaries covering peptides and related drug development. Human trials, laboratory work and company announcements are labelled separately.
Each article links to original sources and explains the study design, findings and open questions. Evidence review dates show when those sources were last checked.
Archive dates refer to earlier research milestones. The actual publication and evidence-review dates remain visible on each article. To flag an error, quote the article and source when contacting Falcon Peps.
The entry notice could not load. Reload the page to continue.
